Background and Aims
Esophageal dilation is a now recognized to be an important therapeutic modality in eosinophilic esophagitis (EoE). We aimed to evaluate the safety of esophageal dilation in EoE, especially regarding perforation risk, and to examine perforation risk by dilator type.
Methods
We conducted a systematic review of the published literature from January 1, 1950 to June 30, 2016 using Pubmed, EMBASE, and Web of Science. Studies were included if they described patients with EoE who underwent esophageal dilation and also reported the presence or absence of at least 1 adverse event (eg, perforation, bleeding, pain, or hospitalization). We used random-effects meta-analysis to estimate the frequency of each adverse event. Adverse event rates are listed as percentages with 95% CI throughout.
Results
Of 923 identified articles, 37 met inclusion criteria and represented 2034 dilations in 977 patients. On meta-analysis, post-procedure hospitalization occurred in 0.689% (0%–1.42%) of dilations, clinically significant GI hemorrhage in 0.028% (0%–0.217%), and clinically significant chest pain in 3.64% (1.73%–5.55%). Nine perforations were documented, a rate of 0.033% (0%– 0.226%) per procedure after meta-analysis. None of the perforations resulted in surgical intervention or mortality. The majority (5/9) were reported before 2009 (rate of 0.41% [0%– 2.75%]); from 2009 forward the rate was 0.030% (0%–0.225%). Dilation method was described in 30 studies (1957 dilations), in which 4 perforations were detected. The estimated perforation rate for bougies was 0.022% (0%–0.347%) and for balloons was 0.059% (0%–0.374%).
Conclusions
Perforation from esophageal dilation in EoE is rare, and there is no evidence of a significant difference in perforation risk related to dilator type. Esophageal dilation should be considered a safe procedure in EoE.